Argenx Se (ARGX) EBITDA Margin Growth (1y) (2017 - 2026)
Argenx Se (ARGX) EBITDA Margin Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,552.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1,276.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1,997.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,276.00 |
| Dec 31, 2025 | 1,461.00 |
| Sep 30, 2025 | 2,824.00 |
| Jun 30, 2025 | 3,071.00 |
| Mar 31, 2025 | 4,105.00 |
| Dec 31, 2024 | 5,101.00 |
| Sep 30, 2024 | 2,696.00 |
| Jun 30, 2024 | 2,839.00 |
| Mar 31, 2024 | 2,413.00 |
| Dec 31, 2023 | 2,896.00 |
| Sep 30, 2023 | 13,438.00 |
| Jun 30, 2023 | 19,534.00 |
| Mar 31, 2023 | 100,485.00 |
| Dec 31, 2022 | 82,138.00 |
| Sep 30, 2022 | -15,887.00 |
| Jun 30, 2022 | 2,062.44 Bn |
| Mar 31, 2022 | 821.98 Bn |
| Dec 31, 2021 | 91,629.00 |
| Sep 30, 2021 | -5,930.00 |
| Jun 30, 2021 | -2,062.44 Bn |